NIAID Launches Clinical Trial of Universal Influenza Vaccine Candidate

National Institute of Allergy and Infectious Diseases sent this bulletin at 06/01/2021 02:47 PM EDT

Tuesday, June 1, 2021

NIAID Launches Clinical Trial of Universal Influenza Vaccine Candidate

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Volunteers will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1, which was developed by scientists from the NIAID Vaccine Research Center.

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).